News und Analysen
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, September 7, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Relay & Fio Corp. Address Market Development and Fionet COVID-19 Applications
- Government, Media, and Doctors Are Aligning on Need for Routine, Controlled Testing at Airports, Workplaces, Homes, and Other Decentralized Locations
- Health Canada
Relay & Fio Corp. prüfen Marktentwicklung und COVID-19-Anwendungen für Fionet
- Regierung, Medien und Ärzte stimmen sich über die Notwendigkeit von routinemäßigen, kontrollierten Tests an Flughäfen, Arbeitsplätzen, zu Hause und an anderen dezentralen Orten
Relay Medical and Fio Corporation Announce Signing Distribution Partners in U.S. & France for the Fionet Mobile COVID-19 Testing and Tracking Platform
- Relay and Fio announce distribution partners in U.S. and France to market Fionet to pharmacies and certain other sectors
- With 10x more locations than hospitals,
Relay Medical und Fio Corporation unterzeichnen Abkommen mit Vertriebspartnern in den USA und Frankreich für mobile COVID-19-Testungs- und Trackingplattform Fionet
- Relay und Fio kooperieren mit Vertriebspartnern in den USA und Frankreich, um Fionet über Apotheken und bestimmte andere Bereiche zu vermarkten.
- Es gibt zehnmal mehr
Antibe Therapeutics to Present at Upcoming Conferences
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences:
LD Micro 500 – Virtual Event
September 1, 2020 - 12:20pm (Eastern Time)
NeutriSci mit Unternehmens-Update über Vertragspartner, neue Märkte und Produktlinien
VANCOUVER, BC / 31. August 2020 / NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) - ein innovatives Technologieunternehmen, das
NeutriSci Provides Corporate Update on Contract Partner, New Markets and Product Line
VANCOUVER, BC / ACCESSWIRE / August 31, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developi
True Leaf Provides Update on Filing of Year End 2020 and First Quarter 2021 Financial Statements
Vernon, BC - August 28, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf” or the “Company”) is providing an update on the status of the filing of its
True Leaf meldet Update zur Einreichung des Jahresabschlusses für 2020 und des Zwischenabschlusses für das erste Quartal 2021
Vernon (British Columbia), 28. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FWB: TLA) („True Leaf“) informiert über den aktuellen Stand der Einreichung seiner Betriebs-
Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform
- Fionet is a first-of-its-kind mobile testing platform for organizations to manage and track on-site COVID-19 testing
- Fionet Devices, usable by non-expert personnel,
Relay Medical und Fio Corporation lancieren mobile COVID-19-Test- und Trackingplattform
- Fionet ist die allererste mobile Testplattform, die es Organisationen ermöglicht, COVID-19-Tests vor Ort zu verwalten und nachzuverfolgen.
- Mit Fionet-Geräten, die
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The
Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information
True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.
Vernon, BC - August 19, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, as part of the sales process approved by Order of the British
True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab
Vernon (British Columbia), 19. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf Pet Inc. („TLP“) im Rahmen des
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J
GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China
GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug
Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform
August 16, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) jointly report that the Companies have extended the me
Relay Medical und Fio Corporation verlängern ihre Absichtserklärung bezüglich der Zusammenarbeit im Hinblick auf eine Schnelltest-Diagnoseplattform
16. August 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) berichten gemeinsam, dass die Unternehmen ihre am
Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien
Vancouver, British Columbia – 12. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
NeutriSci Provides Update Regarding Product Launch in California
Vancouver, British Columbia – August 12, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
- Orphan Drug Designation (ODD) is a status that provides seven years of additional post-approval protection and exemption from filing fees
- Rare Pediatric Disease Designation (RPDD) qualifies the